PLX51107
PLX51107 is a potent and selective BET inhibitor, with Kds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (Kd, in the 100 nM range) .
Product Specifications
CAS Number
1627929-55-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PLX51107.html
Purity
99.98
Solubility
DMSO : 75 mg/mL (ultrasonic)
Smiles
C[C@@H](C1=NC=CC=C1)N2C=C(C3=CC=C(C(O)=O)C=C3)C4=NC=C(C5=C(C)ON=C5C)C=C42
Molecular Formula
C26H22N4O3
Molecular Weight
438.48
Precautions
H302, H315, H319, H335
References & Citations
[1]Ozer HG, et al. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discov. 2018 Apr;8 (4) :458-477.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC743117-500 1x 500 µL
CD19 (B-Lymphocyte Marker) (CD19/3117), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
KN400525 1 Kit
P70 S6 Kinase beta (RPS6KB2) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 
BNCB2171-100 1x 100 µL
Human Kappa Light Chain (B-Cell Marker) (rKLC264), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details